This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Warner Chilcott PLC (WCRX): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Warner Chilcott ( WCRX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.2%. By the end of trading, Warner Chilcott rose $0.25 (1.2%) to $21.29 on average volume. Throughout the day, 5,422,766 shares of Warner Chilcott exchanged hands as compared to its average daily volume of 6,991,800 shares. The stock ranged in a price between $21.05-$21.51 after having opened the day at $21.16 as compared to the previous trading day's close of $21.04. Other companies within the Health Care sector that increased today were: Reliv' International ( RELV), up 54.8%, Synta Pharmaceuticals ( SNTA), up 41.3%, Idera Pharmaceuticals ( IDRA), up 38.0% and Spherix ( SPEX), up 26.3%.

Warner Chilcott Public Limited Company, a specialty pharmaceutical company, engages in the development, manufacture, promotion, and franchise of branded pharmaceutical products focusing on the women's healthcare, gastroenterology, urology, and dermatology markets. Warner Chilcott has a market cap of $5.1 billion and is part of the drugs industry. Shares are down 2.1% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Warner Chilcott a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Warner Chilcott as a hold. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and weak operating cash flow.

On the negative front, Mast Therapeutics ( MSTX), down 37.9%, Pingtan Marine Enterprise ( PME), down 11.1%, Hyperion Therapeutics ( HPTX), down 8.2% and Chelsea Therapeutics International ( CHTP), down 8.1% , were all laggards within the health care sector with Teva Pharmaceutical Industries ( TEVA) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs